"As a leader in cancer diagnostics, Ventana is committed to providing unique immunohistochemistry assays for aiding in the diagnosis and management of a variety of cancers," says Ventana President ...

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced that it has expanded its immunohistochemistry (IHC) test offerings to ...

BOSTON--(BUSINESS WIRE)--Boston Cell Standards, a company standardizing tumor tissue testing with the first immunohistochemistry laboratory reference standards, announced the publication of a journal ...

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the PD-L1 IHC 22C3 PharmDx™ ...

Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test PALO ALTO, Calif.--(BUSINESS WIRE)-- ...

TUCSON, Ariz., Sept. 11, 2013 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced the approval of the VENTANA ALK immunohistochemistry (IHC) assay by ...

On May 21, Guardant Health, Inc. (NASDAQ:GH) announced adding a full suite of immunohistochemistry to its portfolio of tumor molecular profiling tests. This addition will help oncologists identify the ...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (NYSE: A) today announced it has received CE-IVD mark approval for the PD-L1 IHC 28-8 pharmDx to guide options for the first-line ...

Cost-Utility Analysis of Primary Prophylaxis Versus Secondary Prophylaxis With Granulocyte Colony-Stimulating Factor in Elderly Patients With Diffuse Aggressive Lymphoma Receiving Curative-Intent ...

Objective: Routine microsatellite instability and immunohistochemistry screening of colorectal cancers can assist in identifying a significant proportion of cancers attributable to Lynch syndrome.